• Vaccine Name: live attenuated Brucella melitensis strain Rev. 1 delta fba delta tal vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009564
• Type: Live attenuated vaccine
• Status: Research
• Host Species for Licensed Use: Sheep
• Host Species as Laboratory Animal Model: Mus musculus; BeWo trophoblasts; THP-1 macrophages
• Antigen: fructose-bisphosphate aldolase (Fba); transaldolase (Tal)
• Preparation: A double mutant of the Rev. 1 strain with deletions in fba and tal genes, unable to metabolize erythritol. (Elizalde-Bielsa et al, 2024)
• Description: The study proposes that deleting the genes encoding fructose-bisphosphate aldolase (Fba) and transaldolase (Tal) in the Brucella melitensis live-attenuated Rev. 1 vaccine strain blocks erythritol incorporation into central carbon metabolism, potentially reducing placental proliferation and adverse reproductive effects. Efficacy: The Rev1ΔfbaΔtal mutant provided comparable protection to the parental Rev. 1 vaccine in mice. Immune response: Not reported explicitly; however, the mutant showed reduced intracellular fitness and induced fewer adverse reproductive events, suggesting a safer immune profile in pregnant hosts. (Elizalde-Bielsa et al, 2024)

Mouse Response

• Efficacy: The Rev1ΔfbaΔtal mutant provided comparable protection to the parental Rev. 1 vaccine in mice. (Elizalde-Bielsa et al, 2024)
• Description: In vitro intracellular fitness assays in BeWo trophoblasts and THP-1 macrophages; in vivo protection and safety evaluation in a murine model including pregnant animals. (Elizalde-Bielsa et al, 2024)